Atricure Share Price (NASDAQ: ATRC)

$37

▲

-0.22

(-0.59%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Atricure Stock chart to analyse performance

Atricure stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$37.00
Today's High:$37.37
$37.00
0.0%
Downside
Day's Volatility :0.99%
Upside
0.99%
52 Weeks Low:$25.50
52 Weeks High:$43.11
$37.00
31.09%
Downside
52 Weeks Volatility :40.86%
Upside
14.17%

Atricure Stock Returns

Period	Atricure Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	8.79%	3.6%	0.0%
6 Months	-5.06%	-7.7%	0.0%
1 Year	42.6%	-12.6%	0.0%
3 Years	-14.04%	9.5%	-4.7%

Atricure Inc Key Stats

Check Atricure key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$37.22
Open	$37.23
Today's High	$37.37
Today's Low	$37.0
Market Capitalization	$1.8B
Today's Volume	$334.4K
52 Week High	$43.11
52 Week Low	$25.495
Revenue TTM	$499.9M
EBITDA	$-14.1M
Earnings Per Share (EPS)	$-0.77
Profit Margin	-7.27%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-7.85%

Stock Returns calculator for Atricure Stock including INR - Dollar returns

The Atricure stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Atricure investment value today

Current value as on today

₹1,47,921

Returns

₹47,921

(+47.92%)

Returns from Atricure Stock

₹42,637 (+42.64%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Atricure Stock

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Atricure Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Atricure Inc

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
9.87%
BlackRock Inc
8.50%
Wellington Management Company LLP
7.99%
AllianceBernstein L.P.
7.40%
Hood River Capital Management LLC
6.16%
Macquarie Group Ltd
4.90%

Analyst Recommendation on Atricure Stock

Rating

Trend

Buy

93%Buy

6%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Atricure(by analysts ranked 0 to 5 stars)

Atricure Share Price Target

What analysts predicted

Upside of 35.14%

Target:

$50.00

Current:

$37.00

Atricure share price target is $50.00, a slight Upside of 35.14% compared to current price of $37.00 as per analysts' prediction.

Atricure Stock Insights

Price Movement
In the last 1 year, ATRC stock has moved up by 41.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 123.62M → 136.13M (in $), with an average increase of 9.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -15.56M → -6.19M (in $), with an average increase of 69.9% per quarter
ATRC vs ISRG (3 yr)
In the last 3 years, Intuitive Surgical, Inc. has given 25.2% return, outperforming this stock by 44.3%

Atricure Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$230.8M	↑ 14.47%
Net Income	$-35.2M	↑ 66.5%
Net Profit Margin	-15.25%	↓ 4.77%

	FY20	Y/Y Change
Revenue	$206.5M	↓ 10.52%
Net Income	$-48.2M	↑ 36.83%
Net Profit Margin	-23.32%	↓ 8.07%

	FY21	Y/Y Change
Revenue	$274.3M	↑ 32.83%
Net Income	$50.2M	↓ 204.24%
Net Profit Margin	18.3%	↑ 41.62%

	FY22	Y/Y Change
Revenue	$330.4M	↑ 20.43%
Net Income	$-46.5M	↓ 192.56%
Net Profit Margin	-14.06%	↓ 32.36%

	FY23	Y/Y Change
Revenue	$399.2M	↑ 20.84%
Net Income	$-30.4M	↓ 34.49%
Net Profit Margin	-7.62%	↑ 6.44%

	FY24	Y/Y Change
Revenue	$465.3M	↑ 16.55%
Net Income	$-44.7M	↑ 46.85%
Net Profit Margin	-9.61%	↓ 1.99%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$108.9M	↑ 2.17%
Net Income	$-13.3M	↑ 35.55%
Net Profit Margin	-12.19%	↓ 3.0%

	Q2 FY24	Q/Q Change
Revenue	$116.3M	↑ 6.81%
Net Income	$-8.0M	↓ 39.65%
Net Profit Margin	-6.89%	↑ 5.3%

	Q3 FY24	Q/Q Change
Revenue	$115.9M	↓ 0.31%
Net Income	$-7.9M	↓ 1.94%
Net Profit Margin	-6.78%	↑ 0.11%

	Q4 FY24	Q/Q Change
Revenue	$124.3M	↑ 7.22%
Net Income	$-15.6M	↑ 98.24%
Net Profit Margin	-12.53%	↓ 5.75%

	Q1 FY25	Q/Q Change
Revenue	$123.6M	↓ 0.53%
Net Income	$-6.7M	↓ 56.66%
Net Profit Margin	-5.46%	↑ 7.07%

	Q2 FY25	Q/Q Change
Revenue	$136.1M	↑ 10.13%
Net Income	$-6.2M	↓ 8.26%
Net Profit Margin	-4.55%	↑ 0.91%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$170.3M	↑ 15.78%

	FY20	Y/Y Change
Profit	$149.3M	↓ 12.34%

	FY21	Y/Y Change
Profit	$205.9M	↑ 37.88%

	FY22	Y/Y Change
Profit	$245.9M	↑ 19.47%

	FY23	Y/Y Change
Profit	$300.4M	↑ 22.13%

	FY24	Y/Y Change
Profit	$347.5M	↑ 15.7%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$80.5M	↑ 1.84%

	Q2 FY24	Q/Q Change
Profit	$86.1M	↑ 6.9%

	Q3 FY24	Q/Q Change
Profit	$86.8M	↑ 0.82%

	Q4 FY24	Q/Q Change
Profit	$92.6M	↑ 6.71%

	Q1 FY25	Q/Q Change
Profit	$92.6M	↑ 0.01%

	Q2 FY25	Q/Q Change
Profit	$101.5M	↑ 9.56%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-15.8M	↑ 279.07%
Investing Cash Flow	$-2.1M	↓ 97.49%
Financing Cash Flow	$14.4M	↓ 85.65%

	FY20	Y/Y Change
Operating Cash Flow	$-19.9M	↑ 25.67%
Investing Cash Flow	$-156.2M	↑ 7175.17%
Financing Cash Flow	$189.4M	↑ 1217.69%

	FY21	Y/Y Change
Operating Cash Flow	$-13.8M	↓ 30.65%
Investing Cash Flow	$23.5M	↓ 115.05%
Financing Cash Flow	$-7.6M	↓ 104.04%

	FY22	Y/Y Change
Operating Cash Flow	$-22.1M	↑ 60.67%
Investing Cash Flow	$44.0M	↑ 87.23%
Financing Cash Flow	$-7.1M	↓ 7.63%

	FY23	Y/Y Change
Operating Cash Flow	$4.5M	↓ 120.25%
Investing Cash Flow	$21.8M	↓ 50.42%
Financing Cash Flow	$-32.0K	↓ 99.55%

	FY24	Y/Y Change
Operating Cash Flow	$12.2M	↑ 172.17%
Investing Cash Flow	$30.2M	↑ 38.58%
Financing Cash Flow	$-3.6M	↑ 11159.38%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-21.9M	↓ 642.83%
Investing Cash Flow	$9.6M	↓ 446.16%
Financing Cash Flow	$-7.0M	↓ 396.82%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$7.4M	↓ 133.74%
Investing Cash Flow	$30.9M	↑ 220.31%
Financing Cash Flow	$2.0M	↓ 128.48%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$20.0M	↑ 171.06%
Investing Cash Flow	$4.4M	↓ 85.78%
Financing Cash Flow	$-333.0K	↓ 116.7%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$5.8M	↓ 70.83%
Investing Cash Flow	$-14.7M	↓ 434.54%
Financing Cash Flow	$1.7M	↓ 621.92%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-11.0M	↓ 288.93%
Investing Cash Flow	$-1.7M	↓ 88.56%
Financing Cash Flow	$-10.3M	↓ 694.07%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$21.6M	↓ 296.05%
Investing Cash Flow	$-7.7M	↑ 355.8%
Financing Cash Flow	$3.4M	↓ 133.11%

Atricure Technicals Summary

Sell

Neutral

Buy

Atricure is currently in a neutral trading position according to technical analysis indicators.

Atricure Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Atricure Inc	5.38%	-5.06%	42.6%	-14.04%	-17.6%
Intuitive Surgical, Inc.	-2.14%	-16.61%	-2.2%	129.39%	91.27%
Alcon Ag	-9.17%	-15.22%	-16.6%	20.12%	40.07%
West Pharmaceutical Services Inc	3.24%	8.32%	-18.78%	-16.58%	-12.33%
Resmed Inc.	-1.56%	17.91%	12.23%	25.22%	53.62%
Becton, Dickinson And Company	9.36%	-15.57%	-20.36%	-24.43%	-19.91%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Atricure Inc	34.48	NA	-1.18	-0.36	-0.08	-0.04	NA	9.35
Intuitive Surgical, Inc.	66.27	66.27	3.47	8.14	0.16	0.09	NA	49.79
Alcon Ag	36.78	36.78	2.16	3.1	0.05	0.03	0.0	44.73
West Pharmaceutical Services Inc	36.74	36.74	3.55	6.76	0.18	0.11	0.0	40.74
Resmed Inc.	28.99	28.99	1.9	9.5	0.26	0.14	0.01	40.77
Becton, Dickinson And Company	35.34	35.34	0.96	14.37	0.06	0.04	0.02	88.87

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Atricure Inc	Buy	$1.8B	-17.6%	34.48	-7.27%
Intuitive Surgical, Inc.	Buy	$169.9B	91.27%	66.27	28.51%
Alcon Ag	Buy	$39.3B	40.07%	36.78	10.7%
West Pharmaceutical Services Inc	Buy	$17.7B	-12.33%	36.74	16.48%
Resmed Inc.	Buy	$40.3B	53.62%	28.99	27.22%
Becton, Dickinson And Company	Buy	$55.3B	-19.91%	35.34	7.41%

About Atricure Inc

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Organization	Atricure
Employees	1300
CEO	Mr. Michael H. Carrel
Industry	Health Technology

Key Management of Atricure Inc

Name	Title
Mr. Michael H. Carrel	CEO, President & Director
Ms. Angela L. Wirick	Chief Financial Officer
Mr. Douglas J. Seith	Chief Operating Officer
Mr. Karl S. Dahlquist CCEP, J.D.	Chief Legal Officer
Mr. Justin J. Noznesky	Chief Marketing & Strategy Officer
Mr. Salvatore Privitera J.D.	Chief Technical Officer
Dr. Vinayak Doraiswamy Ph.D.	Chief Scientific Officer
Valerie Storch-Willhaus	Vice President of Corporate Marketing & Communications

Important FAQs about investing in ATRC Stock from India :

What is Atricure share price today?

Atricure share price today is $37.00 as on August 30, 2025 at 1:29 am IST at the close of the market. Atricure share today touched a day high of $37.37 and a low of $37.00.

What is the 52 week high and 52 week low for Atricure share?

Atricure share touched a 52 week high of $43.11 and a 52 week low of $25.50. Atricure stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $37.00, lower by 14.17% versus the 52 week high.

How to invest in Atricure Stock (ATRC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Atricure on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Atricure Shares that will get you 0.0405 shares as per Atricure share price of $37.00 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Atricure Stock (ATRC) from India?

Indian investors can start investing in Atricure (ATRC) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Atricure stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Atricure share’s latest price of $37.00 as on August 30, 2025 at 1:29 am IST, you will get 0.2703 shares of Atricure. Learn more about fractional shares .

What are the returns that Atricure has given to Indian investors in the last 5 years?

Atricure stock has given -17.6% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?